PARIS, Nov 27 (Reuters) - Sanofi-Aventis’ experimental heart drug Multaq will be reviewed by an independent expert panel in the United States next March, marking a delay in a priority review by the health regulator.
PARIS, Nov 27 (Reuters) - Sanofi-Aventis’ experimental heart drug Multaq will be reviewed by an independent expert panel in the United States next March, marking a delay in a priority review by the health regulator.
